showed that FBI-1 can inhibit the activity of SP1 in triple negative breast cancer (TNBC) cells, downregulate the expression of miR-30c, and then upregulate the expression of PXR, and ultimately accelerate the antitumor drug Olaparib’s metabolism and clearance rate to induce cell resistance (62). This evidence concerns the gene SP1 and triple-negative breast carcinoma.